Obesity drugs
Zealand Pharma’s stock swings show weight-loss drug market’s new test
Survodutide’s dropout rates cooled enthusiasm, but investors are watching whether amylin-based petrelintide can offer a more tolerable obesity treatment
Zealand Pharma news
Read verified news on BetaVoices covering Zealand Pharma, with reporting, context, and related developments.
#Zealand Pharma
Clear filters
- Experimental obesity drugs Safety questions grow around experimental weight-loss drugs CBS News reported concerns over doctors prescribing retatrutide before FDA approval, while separate trial data for Zealand Pharma’s survodutide rattled investors over side effects
- Obesity drugs Zealand Pharma shares tumble as safety data hit drug hopes Survodutide met late-stage trial goals, but gastrointestinal side effects and a 19% dropout rate raised doubts about its commercial potential